SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-21-019756
Filing Date
2021-08-12
Accepted
2021-08-12 17:08:59
Documents
71
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20210630_10q.htm   iXBRL 10-Q 1372647
2 EXHIBIT 31.1 ex_272367.htm EX-31.1 10252
3 EXHIBIT 32.1 ex_272368.htm EX-32.1 6198
  Complete submission text file 0001437749-21-019756.txt   6913040

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA navb-20210630.xsd EX-101.SCH 59681
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20210630_cal.xml EX-101.CAL 39488
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20210630_def.xml EX-101.DEF 502596
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20210630_lab.xml EX-101.LAB 372035
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20210630_pre.xml EX-101.PRE 522757
9 EXTRACTED XBRL INSTANCE DOCUMENT navb20210630_10q_htm.xml XML 990134
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 211168624
SIC: 2835 In Vitro & In Vivo Diagnostic Substances